Lower dose of letrozole for early breast cancer
Treatments studied
This trial tests if a lower dose of the hormone therapy drug letrozole can work as well as the standard dose for people with early-stage hormone receptor-positive breast cancer. The lower dose may cause fewer side effects while still helping to prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with early-stage breast cancer (stage I to III) that has not spread far.
- Your tumor tests positive for estrogen receptors (ER positive) and negative for HER2.
- You are postmenopausal and were female at birth.
- You are 18 years or older and are planning to have surgery for your breast cancer before starting any other treatment.
- You have not received any prior treatment for this breast cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This trial tests whether taking hormone therapy for 3 months before breast-conserving surgery can help doctors decide if radiation is right for you. It is for women aged 65 and older with a common type of breast cancer that is hormone receptor-positive and HER2-negative.
This trial is testing a lower dose of treatment for women with small, early-stage breast cancer that is hormone-positive and has not spread to lymph nodes. The goal is to find out if it can be as effective as the standard treatment with fewer side effects.
This trial tests whether taking letrozole, a hormone-blocking pill, before surgery can help shrink estrogen-positive breast cancer. It is for women who have gone through menopause and have early-stage cancer that has spread to nearby lymph nodes.
This study tests whether letrozole, a hormone-blocking medicine, can help people with newly diagnosed low-grade serous ovarian cancer that has hormone receptor proteins (ER and/or PgR) after surgery. It compares outcomes to see if blocking estrogen can slow the cancer’s return or progression.
This Phase 3 trial studies whether “less intense” radiation can work as well as standard radiation for certain early-stage hormone receptor–positive, HER2-negative breast cancers that have a low Oncotype DX score. It may help reduce treatment burden while keeping cancer control strong.
Hear when a new Brest Cancer ER+ and HER2 Negative trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.